EMA Reinforces GCP By Ruling Out Data Replacement
This article was originally published in SRA
When a pivotal clinical study in a centralized marketing application has been found to be non-GCP compliant, it cannot simply be replaced with another, GMP-compliant, study. Companies must re-submit the marketing application, the European Medicines Agency says in a position paper issued Nov. 301,2.
Register for our free email digests: